Nasus Pharma Ltd. (NYSEAMERICAN:NSRX – Get Free Report) CEO Dan Benjamin Teleman purchased 6,550 shares of the firm’s stock in a transaction on Wednesday, June 17th. The shares were acquired at an average cost of $3.10 per share, with a total value of $20,305.00. Following the completion of the acquisition, the chief executive officer directly owned 163,541 shares in the company, valued at $506,977.10. The trade was a 4.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Dan Benjamin Teleman also recently made the following trade(s):
- On Wednesday, April 22nd, Dan Benjamin Teleman acquired 2,900 shares of Nasus Pharma stock. The shares were bought at an average cost of $3.76 per share, for a total transaction of $10,904.00.
Nasus Pharma Stock Performance
Shares of NYSEAMERICAN:NSRX opened at $3.07 on Monday. The stock’s fifty day moving average is $2.94. Nasus Pharma Ltd. has a 12 month low of $1.98 and a 12 month high of $9.99.
Analysts Set New Price Targets
Read Our Latest Research Report on NSRX
About Nasus Pharma
Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions. Nasus Pharma Ltd. is based in TEL AVIV, Israel.
Further Reading
- Five stocks we like better than Nasus Pharma
- SpaceX’s Historic IPO Has Already Sparked a 2X ETF Frenzy
- Cheesecake Factory Stock Is Up Over 50%—Is There Room for More CAKE?
- Royal Caribbean’s Best Quarter Ever Still Leaves a Big Question
- Lululemon’s China Backlash May Be Hiding a Bigger Valuation Story
Receive News & Ratings for Nasus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nasus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
